Clinical trials: Lymphedema, Secondary
- Condition Lymphedema, Secondary
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Breast Cancer Related Lymphoedema, Lymphoedema
LYT-100 in Patients With BCRL
This is a trial of up to 6-months duration for safety, tolerability, clinical efficacy assessments, PK and biomarkers analysis in breast carcinoma patients with secondary lymphoedema
- Trial name
- NCT04243837
- Testing
- LYT-100 BCRL
- Where
- 8 sites in United States, Australia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- PureTech